Featured post


Cancer Center TV scans, reposts via attribution and curates high quality cancer related videos from best practices in allopathic medicine to the emerging evidence base in integrative oncology.

This session is courtesy of the Dana-Farber/Brigham and Women’s Cancer Center and focuses on ‘integrative oncology’ modalities.

The original source link is here.

The session originally streamed live on Feb 19, 2014 and features David Rosenthal, MD, medical director of Dana-Farber’s Zakim Center for Integrative Therapies.

Dr Rosenthal discusses acupuncture, meditation, yoga, massage, and other forms of integrative therapy used to ease cancer-related symptoms.

Do you have a question for Dr. Rosenthal? Email webchats@dfci.harvard.edu. More information on the Zakim Center is available here.

Reports From the German High-Grade Lymphoma Study Group on Diffuse Large B-Cell Lymphoma

by Gregg A. Masters, MPH

This video via ASCO Post is sourced from ASCO’s 50th Annual Meeting in Chicago.

In this clip:

‘Dr. Jim Armitage, of the University of Nebraska Medical Center, speaks with Michael Pfreundschuh, of the Universitaetsklinikum des Saarlandes in Homburg, Germany about research presented at ASCO’s 50th Annual Meeting by the German High-Grade Lymphoma Study Group. In particular, Drs. Armitage and Pfreundschuh discuss the results of the phase II SEXIE-R-CHOP-14 trial in which researches found that increasing the dose of rituximab by one-third, from 375 mg/m2 to 500 mg/m2, eliminated any gender-related differences in survival outcomes among elderly patients with aggressive CD20+ B-cell lymphomas.’

For original source click here.

The State of Cancer Care in the U.S. via @ASCO

By Gregg A. Masters, MPH

‘ASCO’ the American Society of Clinical Oncology does great work… here’s just one example.

The State of Cancer Care in America

From the report:

The State of Cancer Care in America: 2014 report—released by the American Society of Clinical Oncology (ASCO) and published by the Journal of Oncology Practice here —is the first-ever, comprehensive look at demographic, economic, and oncology practice trends that will impact cancer care in the United States over the coming years.

With recommendations for addressing the cancer care delivery system’s most pressing concerns, this landmark ASCO report also examines the rapid expansion of health information technology and the growing emphasis on quality measurement and value.

ASCO developed the State of Cancer Care in America: 2014report to help cancer care providers, policy makers, and others more effectively shape the future of cancer care during these uncertain times. The Society will issue annual updates that will track trends and identify emerging issues.

Notes: The American Society of Clinical Oncology has released its first ever report on the State of Cancer Care in America. Peter Yu, MD, FASCO, discusses the report’s findings. Go here to learn more and follow ASCO on twitter via @asco.


Biomarkers in Context: Prostate Cancer

By Gregg A. Masters, MPH

This clip courtesy of The Oncologist (follow via @OncJournal):

The timely session considers the question: ‘What answer in context is the biomarker result(s) intended to inform? How can or will it impact treatment decisions?

‘if we’re going to move forward it is essential that we can actually make measurements that are going mean something..’

Faculty: Howard I. Scher, MD, Chief, Genitourinary Oncology Service; D. Wayne Calloway Chair in Urologic Oncology, Memorial Sloan Kettering Cancer Center (follow via @Sloan_Kettering).


First-Line ER-Positive Metastatic Breast Cancer Treatments

By Gregg A. Masters, MPH

This article sourced from ONClive.

Treatment of estrogen receptor (ER)-positive breast cancer can be complicated and depends on many factors, such as disease burden and the duration of a patient’s disease-free interval from the original diagnosis.

For example, a patient with lymph node soft tissue, such as pleural or bone metastatic disease, would be treated differently than a patient with highly proliferative, liver-predominant, extensive visceral disease.

Joanne Blum, MD, notes that the patient in the latter scenario who is symptomatic would receive chemotherapy up front to control the extensive burden of disease, usually with 2 agents to achieve a rapid response.

To read more..